cilazapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 641 88768-40-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cilazapril monohydrobromide
  • cilazapril anhydrous
  • cilazapril
  • inhibace
  • vascace
  • cilazapril monohydrate
  • cilazapril hydrate
One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.
  • Molecular weight: 417.51
  • Formula: C22H31N3O5
  • CLOGP: 1.47
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 99.18
  • ALOGS: -2.59
  • ROTB: 9

Drug dosage:

DoseUnitRoute
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.34 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SYK,TEK,TGFBR1 25
kinase-selectivity-class AXL,BRAF,EPHB4,GRK2,MAP2K6,STK33,TEK 7
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Labile hypertension 135.91 43.95 18 604 497 90627328
Labelled drug-drug interaction medication error 70.63 43.95 17 605 14565 90613260
Tinnitus 64.89 43.95 20 602 43082 90584743
Myalgia 55.63 43.95 26 596 175099 90452726
Chest pain 46.04 43.95 28 594 319617 90308208

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pacemaker generated rhythm 62.35 34.34 8 735 62 42620530
Antiacetylcholine receptor antibody positive 59.34 34.34 8 735 94 42620498
Heart rate abnormal 34.66 34.34 8 735 2231 42618361

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Labile hypertension 114.90 42.01 18 2058 581 110586642
Tinnitus 89.83 42.01 36 2040 60504 110526719
Amaurosis fugax 84.05 42.01 17 2059 2373 110584850
Head discomfort 73.31 42.01 23 2053 18977 110568246
Myalgia 61.83 42.01 43 2033 222338 110364885
Pacemaker generated rhythm 61.29 42.01 8 2068 66 110587157
Urinary tract disorder 58.93 42.01 15 2061 5829 110581394
Haemorrhagic stroke 54.47 42.01 17 2059 13772 110573451
Ocular discomfort 53.31 42.01 15 2061 8518 110578705
Antiacetylcholine receptor antibody positive 50.64 42.01 8 2068 272 110586951

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA08 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA08 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50266 prodrug
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs
benazeprilcaptoprildelaprilenalaprilfosinoprilimidaprillisinoprilmoexiprilperindoprilquinaprilramiprilspirapril show all 15 →
C09BA ACE inhibitors and diuretics 11 drugs
benazeprilcaptoprildelaprilenalaprilfosinoprillisinoprilmoexiprilperindoprilquinaprilramiprilzofenopril

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.93 acidic
pKa2 7.61 Basic
pKa3 3.71 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 8.70 WOMBAT-PK SCIENTIFIC LITERATURE

External reference:

IDSource
4025239 VUID
N0000171771 NUI
D01069 KEGG_DRUG
92077-78-6 SECONDARY_CAS_RN
152491 RXNORM
C0055723 UMLSCUI
CHEBI:145568 CHEBI
CHEMBL515606 ChEMBL_ID
D017315 MESH_DESCRIPTOR_UI
DB01340 DRUGBANK_ID
56330 PUBCHEM_CID
6459 IUPHAR_LIGAND_ID
19KW7PI29F UNII
DB15565 DRUGBANK_ID
003950 NDDF
1268982005 SNOMEDCT_US
318913001 SNOMEDCT_US
395947008 SNOMEDCT_US
725786001 SNOMEDCT_US
C0055724 UMLSCUI
CHEMBL2104578 ChEMBL_ID
5675 INN_ID
90139-06-3 SECONDARY_CAS_RN
64766 PUBCHEM_CID
6461 IUPHAR_LIGAND_ID
5811 INN_ID
4025239 VANDF
C045980 MESH_SUPPLEMENTAL_RECORD_UI
WBL76FH528 UNII
CHEBI:81005 CHEBI
19KW7PI29F INXIGHT DRUGS
WBL76FH528 INXIGHT DRUGS

Pharmaceutical products:

None